Diametric Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Diametric Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$458K	Sell	18,487 -7,966	-30%	-$190K	0.12%	239
2025 Q4	$617K	Buy	+26,453	New	+$589K	0.17%	180
2024 Q1	–	Sell	-17,336	Closed	-$291K	–	350
2023 Q4	$291K	Sell	17,336 -14,511	-46%	-$198K	0.18%	162
2023 Q3	$372K	Buy	+31,847	New	+$426K	0.16%	188
2019 Q3	–	Sell	-50,657	Closed	-$195K	–	106
2019 Q2	$195K	Buy	+50,657	New	+$219K	0.12%	109

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Diametric Capital's CPRX Position: Q1 2026 in Review

Diametric Capital reduced its Catalyst Pharmaceutical (CPRX) stake by 30% in Q1 2026, selling an estimated $190K and leaving 18,487 shares worth $458K. The position accounts for 0.12% of the portfolio, ranked #239.

Diametric Capital first reported a position in CPRX in Q2 2019 and has held it in 5 quarters since. The position peaked at $617K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Diametric Capital held 18,487 shares of Catalyst Pharmaceutical worth $458K as of Q1 2026.
Diametric Capital sold 7,966 Catalyst Pharmaceutical shares in Q1 2026, an estimated $190K.
Catalyst Pharmaceutical made up 0.12% of Diametric Capital's portfolio in Q1 2026, its #239 holding.
Diametric Capital first reported a position in Catalyst Pharmaceutical in Q2 2019 and has held it in 5 quarters since.
Diametric Capital's Catalyst Pharmaceutical position peaked at $617K in Q4 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.